drugset / Trial / NCT02251184

Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

NCT02251184

Phase 4 Completed 31 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Comparison of pharmacokinetics of dipyridamole administered as Aggrenox versus dipyridamole administered as the immediate release formulation plus aspirin, under conditions of reduced stomach acidity.

Timeline

Start
2000-10
Primary completion
2000-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Aggrenox Unknown
Comparator Dipyridamole Other / unclassified
Comparator Aspirin Small molecule
Background Lansoprazole Other / unclassified

Indications

No indication recorded.